An observational study assessing the impact of anti-citrullinated antibody (ACPA) in rheumatoid arthritis (RA) participants who have received abatacept or tumour necrosis factor inhibitors (TNFi) from the Optimising Patient outcome in Australian rheumatoLogy (OPAL) registry
Study Type
OBSERVATIONAL
Enrollment
2,052
Non-Interventional
Non-Interventional
Unnamed facility
Canberra City, Australia
ACPA (Anti-cyclic citrullinated peptide) status
ACPA-positive greater than or equal to 5 Ru/mL in Australia, greater than or equal to 20 Ru/mL in US
Time frame: Pre-Index
Number of participants with positive ACPA
ACPA-positive greater than or equal to 5 Ru/mL in Australia, greater than or equal to 20 Ru/mL in US
Time frame: Index
Number of participants with negative ACPA
ACPA-negative less than or equal to 5 Ru/mL in Australia, less than or equal to 20 Ru/mL in US
Time frame: Index
CDAI (clinical disease activity index) score
Remission CDAI \<2.9 Low disease activity CDAI ≥ 2.9 but \<10.0 Moderate disease activity CDAI ≥ 10.1 but \<22.0 High disease activity CDAI ≥ 22.0
Time frame: Index plus or minus 1 month
CDAI (clinical disease activity index) score
Remission CDAI \<2.9 Low disease activity CDAI ≥ 2.9 but \<10.0 Moderate disease activity CDAI ≥ 10.1 but \<22.0 High disease activity CDAI ≥ 22.0
Time frame: 12 months plus or minus 3 months
DAS28 (disease activity score 28)-CRP-3 (C reactive protein) score
The DAS-28 CRP-3 is a measure of disease activity in rheumatoid arthritis (RA) that assesses 28 joints in RA commonly affected. The DAS-28 CRP 3 takes into account tender and swollen joint counts and CRP level (measure of inflammation in the blood). The DAS-28 CRP 3 measure does not include patient global assessment of health.
Time frame: Index plus or minus 1 month
DAS28 (disease activity score 28)-CRP-3 (C reactive protein) score
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
The DAS-28 CRP-3 is a measure of disease activity in rheumatoid arthritis (RA) that assesses 28 joints in RA commonly affected. The DAS-28 CRP 3 takes into account tender and swollen joint counts and CRP level (measure of inflammation in the blood). The DAS-28 CRP 3 measure does not include patient global assessment of health.
Time frame: 12 months plus or minus 3 months
Number of participants with treatment persistence
Time frame: Approximately 11 years and 5 months
Number of participants with treatment discontinuation
Time frame: Approximately 11 years and 5 months
Number of participants identified as taking abatacept
Time frame: Index
Number of participants identified as taking TNFi (tumor necrosis factor inhibitor)
Time frame: Index
Number of participants that achieved remission
Remission CDAI \<2.9 Low disease activity CDAI ≥ 2.9 but \<10.0 Moderate disease activity CDAI ≥ 10.1 but \<22.0 High disease activity CDAI ≥ 22.0
Time frame: 12 months plus or minus 3 months